Ontology highlight
ABSTRACT: Background
BRCA1/2 mutations lead to an elevated risk of breast cancer. None involved in whether BRCA1/2 mutation status will affect the first decision-making of sentinel lymph node (SLN) biopsy or not for clinically node-negative breast cancer. We retrospectively investigated whether BRCA1/2 mutation status influenced SLN involvement rate and survival outcomes after sentinel lymph node biopsy (SLNB) for Chinese clinically node-negative breast cancer patients.Methods
Patients who underwent SLNB at initial were enrolled and divided according to BRCA1/2 mutation status. Germline DNA for BRCA1/2 testing was derived from blood samples. SLN involvement rate and clinicopathological characteristics were analyzed using the Chi-square test. Kaplan-Meier univariate and multivariate Cox regression analysis was performed to compare survival between groups.Results
According to BRCA1/2 mutation test criteria, 156 Chinese women receiving initial SLNB with clinically node-negative breast cancer were selected-thirty-one patients identified as BRCA1/2 mutation carriers and 102 as non-carriers were enrolled. Non-carriers seemed to be with a more advanced TNM stage (P<0.01) compared to the non-carrier group. Once SLN involved, the patient will receive axillary lymph node dissection in which BRCA1/2 mutation did not increase the rate (P=0.73). Disease-free survival (DFS) (P=0.48) and recurrence-free survival (RFS) (P=0.79) are comparable between groups, even after adjustment for clinicopathological characteristics, systemic treatment, and surgical management of breast [DFS, hazard ratio (HR) =1.63, confidence interval (CI): 0.48-5.54, P=0.43; RFS, HR =0.75, CI: 0.14-3.89, P=0.73].Conclusions
SLNB should be considered for clinically node-negative breast cancer regardless of BRCA1/2 status.
SUBMITTER: Huang X
PROVIDER: S-EPMC7576024 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
Annals of translational medicine 20200901 18
<h4>Background</h4><i>BRCA1/2</i> mutations lead to an elevated risk of breast cancer. None involved in whether <i>BRCA1/2</i> mutation status will affect the first decision-making of sentinel lymph node (SLN) biopsy or not for clinically node-negative breast cancer. We retrospectively investigated whether <i>BRCA1/2</i> mutation status influenced SLN involvement rate and survival outcomes after sentinel lymph node biopsy (SLNB) for Chinese clinically node-negative breast cancer patients.<h4>Met ...[more]